Mongoose Bio

Executive Summary

Mongoose Bio is an early-stage biotechnology company revolutionizing T cell therapies for solid tumors through a unique epigenetic reprogramming approach. Founded in 2021 and headquartered in San Diego, the company develops autologous Tcm (central memory T) cells engineered with defined, empirically-validated TCRs targeting highly immunogenic tumor antigens. This method aims to overcome key limitations of conventional adoptive T cell therapies, such as poor persistence and limited efficacy against solid tumors. By reprogramming T cells epigenetically, Mongoose Bio seeks to generate active, durable TCR-T therapeutics with improved tumor infiltration and reduced exhaustion. The company is privately held and has not disclosed total funding or valuation, indicating it is likely in early preclinical or IND-enabling stages. Despite limited public information, Mongoose Bio's differentiated platform addresses a critical need in oncology, positioning it as a potential player in the next generation of cell therapies.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead TCR-T Program60% success
• Q4 2026Series A Financing Announcement70% success
• Q2 2026Preclinical Data Presentation at Major Conference80% success